(Press-News.org) American and Spanish researchers have found potential ways for doctors to improve the treatment of hormone receptor-positive breast cancer even if they lack access to costly multi-gene tests, as they report at the 4th IMPAKT Breast Cancer Conference.
Because breast cancer is a biologically and clinically varied disease, doctors aim to choose appropriate treatments based on the characteristics of each patient's individual tumor. In the past, this has been done using pathology-based biomarkers; however these do not capture the full diversity of cancers.
"In this context, tests based on multi-gene expression have been shown to provide valuable information beyond the pathology-based biomarkers," says Dr Aleix Prat from the University of North Carolina, Chapel Hill. "However, multi-gene tests are not readily available in most of the world due to cost, assay turnaround times and other logistic issues."
Dr Prat and colleagues addressed this problem by trying to improve the current pathology-based biomarkers to better represent data coming from a particular multi-gene test known as the PAM50 breast cancer intrinsic classifier.
"The PAM50 breast cancer intrinsic classifier identifies two major groups of hormonal receptor-positive breast cancer known as the Luminal A and Luminal B subtypes. These two molecular entities have different risks of relapse and responses to chemotherapy," Dr Prat said.
Alongside the development of this multi-gene assay, clinicians have devised pathology-based surrogate assays for the identification of both the Luminal A and Luminal B subtypes. "In the absence of multi-gene assays, the pathology-based assays are clinically valuable," Dr Prat explained. "However, we observed that the current pathology-based definitions of the Luminal A and Luminal B subtypes still show a 30-40% discordance rate compared to multi-gene tests such as the PAM50 breast cancer intrinsic classifier."
The researchers examined differences in gene expression patterns between Luminal A and Luminal B tumors using the PAM50 test. They also collected clinical-pathological features from 2,950 primary tumors across four independent studies. Using statistical methods, they tested the independent prognostic significance of those features.
They found that the expression of progesterone receptor was one of the most discriminatory molecules. "Addition of quantitative scoring of the progesterone receptor into the current pathology-based Luminal A definition appears to better identify the subgroup of patients that have an outstanding survival when treated with endocrine therapy alone, and therefore do not need systemic chemotherapy," Dr Prat said. "This subpopulation of patients is likely to represent around 30% of the patients with low-risk pathology-defined Luminal A tumors."
"Current pathology-based definitions of the Luminal A and Luminal B subtypes are valuable, but can be improved for the management of hormonal receptor-positive breast cancer," the researcher concluded. "We believe that we have an improvement based upon the progesterone receptor, and given that progesterone receptor is widely used, our improvement could be widely and quickly adopted, if further validated."
According to Dr Di Leo, Hospital of Prato, Italy, former IMPAKT Chair, this is an important study with practical implications, because it tells us that the evaluation of the progesterone receptor along with the evaluation of other biomarkers, such as the estrogen receptor, proliferation markers and c-erbB2, may be relevant to better define the biological profile of the tumor. "This is a critical step towards a personalized medicine approach in breast cancer. It will be important to test the progesterone receptors according to a standardized approach across the pathology departments. One potential concern, in fact, could be the use of different techniques for the progesterone receptors evaluation, which might lead to discordant results between different pathology labs."
INFORMATION:
END
Tubal ectopic pregnancy (TEP) is currently the leading cause of pregnancy-related deaths during the first trimester and a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM) shows that the hormone adrenomedullin (ADM) may help predict this condition.
TEP is a condition where the fertilized egg implants in the fallopian tubes instead of in the uterus. In pregnant women, cilia (small protuberances) pulsate, or beat, to propel an embryo through the fallopian tubes towards the uterus. Defects in ciliary beats ...
New findings presented at Europe's leading breast cancer translational research conference this year shed new light on the many biological differences between individual breast cancers.
Focused on the biological features that make tumors more or less sensitive to important therapies, the new studies will help doctors make crucial choices about the most appropriate treatment for millions of patients.
"Despite major advances in the treatment of breast cancer many patients continue to relapse and die from the disease," noted Prof Mitch Dowsett from the Royal Marsden Hospital, ...
A new analysis may help doctors identify breast cancer patients who will benefit from treatment with the immune suppressant drug everolimus, say French researchers at the 4th IMPAKT Breast Cancer Conference in Brussels, Belgium.
Everolimus is currently used as an immunosuppressant to prevent patients rejecting transplanted organs and in the treatment of renal cell cancer. Research is also being conducted into the drug's use in other cancers, including breast cancer.
Dr Thomas Bachelot, from Centre Leon Berard in Lyon and colleagues analyzed data from the TAMRAD study, ...
Breast cancer patients whose tumors express high levels of genes related to immune response are more likely to have their tumor completely eradicated by pre-operative chemotherapy compared to patients with low expression of these genes, Belgian researchers report at the 4th IMPAKT Breast Cancer Conference in Brussels, Belgium.
Their research has identified a group of patients who might be good candidates for treatments with new immune-targeting therapies.
Dr Michail Ignatiadis from Institut Jules Bordet, Brussels, and colleagues analyzed gene expression data from eight ...
Breast cancer in young women is a biologically unique disease that requires customized management strategies, researchers report at the 4th IMPAKT Breast Cancer Conference, in Brussels, Belgium.
The reported findings have potentially important implications for treatment, because breast cancer in young women is often aggressive and diagnosed at an advanced stage, meaning the prognosis for these patients is often poor.
Dr. Hatem A. Azim Jr., a medical oncologist from Institut Jules Bordet in Brussels, and colleagues showed that breast cancer in women forty-years or younger ...
CHAPEL HILL, N.C. – Embryonic stem cells — those revered cells that give rise to every cell type in the body — just got another badge of honor. If they suffer damage that makes them a threat to the developing embryo, they swiftly fall on their swords for the greater good, according to a study published online May 3, 2012 in the journal Molecular Cell.
The finding offers a new glimpse into the private lives of stem cells that could help scientists use them to grow new neurons or other cells to replace those that have been lost in patients with Parkinson's and other diseases. ...
May 3, 2012, New York, NY—The United States spends more on health care than 12 other industrialized countries yet does not provide "notably superior" care, according to a new study from The Commonwealth Fund. The U.S. spent nearly $8,000 per person in 2009 on health care services, while other countries in the study spent between one-third (Japan and New Zealand) and two-thirds (Norway and Switzerland) as much. While the U.S. performs well on breast and colorectal cancer survival rates, it has among the highest rates of potentially preventable deaths from asthma and amputations ...
LA JOLLA, CA – May 3, 2012 - What genetic changes account for the vast behavioral differences between humans and other primates? Researchers so far have catalogued only a few, but now it seems that they can add a big one to the list. A team led by scientists at The Scripps Research Institute has shown that an extra copy of a brain-development gene, which appeared in our ancestors' genomes about 2.4 million years ago, allowed maturing neurons to migrate farther and develop more connections.
Surprisingly, the added copy doesn't augment the function of the original gene, ...
PULLMAN, Wash.—Washington State University researchers have found that ovarian disease can result from exposures to a wide range of environmental chemicals and be inherited by future generations.
WSU reproductive biologist Michael Skinner and his laboratory colleagues looked at how a fungicide, pesticide, plastic, dioxin and hydrocarbon mixtures affected a gestating rat's progeny for multiple generations. They saw subsequent generations inherit ovarian disease by "epigenetic transgenerational inheritance." Epigenetics regulates how genes are turned on and off in tissues ...
Patients in an intensive care unit (ICU) often become confused or delirious soon after, or within a few days of, admittance to the ICU. New research published in BioMed Central's open access journal Critical Care shows that use of earplugs can result in better sleep (as reported by the patients), lower the incidence of confusion, and delay the onset of cognitive disturbances.
Patients in the ICU are thought to suffer confusion and delirium due to sensory overload. Part of this is due to the physical injuries and sensations of the patients and part due to their environment. ...
